Whitener Capital Management Inc. Has $3.97 Million Stake in Johnson & Johnson (NYSE:JNJ)

Whitener Capital Management Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,312 shares of the company’s stock after selling 77 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Whitener Capital Management Inc.’s portfolio, making the stock its 11th largest position. Whitener Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,971,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $39,000. Cardinal Capital Management Inc. increased its position in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the period. First Bank & Trust raised its stake in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $84,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ stock opened at $173.43 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company’s 50-day moving average is $176.33 and its 200-day moving average is $171.44. The stock has a market capitalization of $453.43 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.60 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. StockNews.com initiated coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Bank of America cut their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Barclays began coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Finally, Sanford C. Bernstein lowered their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $182.42.

Insiders Place Their Bets

In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,707,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 300,750 shares of company stock worth $52,311,677. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.